Dr. Frank Hull MD
Follow link for current research
Training
I Graduated from University of Pretoria Medical School in South Africa in 1990, my training since then includes working/training in 4 countries. This includes
Pre USA training
Family Practice Training and Experience
1990, Medical School: Graduated University of Pretoria.
1991, Internship, Edendale Hospital, Pietermaritzburg. Surgery, Obstetrics and Gynecology, Orthopedics, and Internal Medicine,
1992, Clinical Chemistry at the University of Natal, Durban, Pediatrics at the University of Pretoria
1992-1993, Family Medicine, Private Practice: Humboldt, Saskatchewan Canada. I moved to avoid the mandatory apartheid military conscription of South Africa.
1994, Jan-June: House officer. Accident and Emergency Medicine in Nuneaton, England.
USA training
1994, July: 3 year Internal Medicine Residency. Albert Einstein College of Medicine, Bronx NY.
1997, July 3 year Pulmonary Critical Care Fellowhip. NYU Medical Center - Bellevue
2000, July 1.5 year Sleep Medicine Fellowship and Research Fellowship at NYU Medical Center - Bellevue Hospital completing training 2001.
2002 faculty at Albert Einstein College of Medicine, Assistant Professor in Medicine.
Current Practice
July 2003 I joined “Broward Pulmonary and Sleep Specialists” in Fort Lauderdale Florida, a Private Practice specializing in Pulmonary/Critical Care and Sleep Medicine.
2015 Managing partner “Broward Pulmonary and Sleep Specialists”.
Faculty Achievements
Jan 2011 - present Full Clinical Professor of Medicine
Jan 2004 - 2011Assistant, then Associate Professor of Medicine
Nova Southeastern University
Jan 2002 – July 2003 Assistant Professor of Medicine, Albert Einstein College of Medicine, Bronx, NY
Medical Intensive Care Unit and Pulmonary Service
Jacobi and North Central Bronx Hospitals
DIPLOMAS & CERTIFICATIONS
1990 M.D. Degree University of Pretoria. South Africa
1992 G.M.C. General Medical Council; Full Licensure, United Kingdom.
1993 L.M.C.C. Full Licensure Medical Council of Canada.
1993 F.L.E.X. Components 1 - 86% and 2 - 86%.
1993 F.M.G.E.M.S. Components 1 - 84% and 2 - 84%.
1997 Board Certified in Internal Medicine
2007 American Board of Internal Medicine.
1999 Board Certified in Pulmonary Medicine
2009 and 2019 Recertified American Board of Internal Medicine.
2000 Board Certified in Critical Care
2010 Recertified American Board of Internal Medicine.
2003 and 2011 Dual Board Certified in Sleep Disorders Medicine.
American Board of Sleep Medicine (2003) and American Board of Internal Medicine (2011).
LICENSES
1990 - South African Medical Council
1993 - Saskatchewan, License Canada (inactive)
1994 - United Kingdom Medical Council
1997 - New York State License (inactive)
1998 - Indiana State License (inactive)
2003 - Florida State License (active)
PROFESSIONAL ORGANIZATIONS
American Thoracic Society (ATS).
American Academy of Sleep Medicine (AASM), Fellow.
American College of Chest Physicians (ACCP).
American College of Physicians (ACP).
Broward County Medical Association (BCMA), Executive Board Member since 2016.
Florida Medical Association (FMA).
Caducean Society Fort Lauderdale, President 2016-2017.
Pulmonary Hypertension Association, Professional Member & Speaker.
RESEARCH PUBLICATIONS
1999 High Levels of Plasma IL-10 does not diminish purified protein derivative (PPD) skin induration size, FP Hull, R Condos, WN Rom:
AJRCCM Vol 159 (3) March 1999 pg A555.
Presented at American Thoracic Society International Conference in San Diego.
2000 Clinical Efficacy Of Long Term Treatment With Pyrazinamide (PZA) In Multi Drug Resistant Tuberculosis (MDR-TB).
Presented at American Thoracic Society (ATS) International Conference in Toronto
2001 1. Deposition of aerosolized interferon gamma in patients with tuberculosis. F.P. Hull, R.Condos, W.N.Rom, G.C. Smaldone
2. A novel method for measuring upper airway aerosol deposition.
F.P. Hull, R. Condos, W.N. Rom, G.C. Smaldone.
Posters presented at ATS May 2000 San Francisco
2001 Predicting Lung Deposition with a Cascade Impactor. Sangwan S, Hull F, Condos R, Smaldone GC.
Journal of Aerosol Medicine 2001; 14(3): 421
2004 Regional Deposition of Aerosolized Interferon- in Pulmonary Tuberculosis*
Rany Condos, MD; Frank P. Hull, MD; Neil W. Schluger, MD, FCCP; William N. Rom, MD, MPH, FCCP and Gerald C. Smaldone, MD, PhD, FCCP Chest. 2004;125:2146-2155
2005 American Academy of Sleep Medicine Poster Presentation Denver June 2005:
‘Assessing Fatigue in Commercial Airline Pilots Using The Trail Making Test’: Llewellyn Boyer-Cartwright, Stephanie Silberman Ph.D. , Frank Hull M.D.
2018 American Academy of Sleep Medicine Poster Presentation Denver June 2005:
‘Assessing Fatigue in Commercial Airline Pilots Using The Trail Making Test’: Llewellyn Boyer-Cartwright, Stephanie Silberman Ph.D. , Frank Hull M.D.
Venous Thromboembolism in Acute Medically Ill Patients: Identifying Unmet Needs and Weighing the Value of Prophylaxis .Paul P. Dobesh, PharmD, Tania Ahuja, PharmD, George A. Davis, PharmD, Hugh Fatodu, MBA, RPh, William H. Francis, MBA, RPh, Frank P. Hull, MD, Gary L. Johnson, MD, MS, MBA, Joshua D. Lenchus, DO, BSPharm, Jacqueline Glee Lenoir, PharmD, Claudette McPherson, RN, BSN, Jeffrey Nemeth, PharmD, MPA, Ralph J. Riello III, PharmD Am J Manag Care. 2018;24:-S0
Best practices for implementing venous thromboembolism prophylaxis across the continuum of care Paul P Dobesh 1, Tania Ahuja, George A Davis, Hugh Fatodu, William H Francis, Frank P Hull, Gary L Johnson, Joshua D Lenchus, Jacqueline Glee Lenoir, Claudette McPherson, Jeffrey Nemeth, Ralph J Riello 3rd Am J Manag Care 2018 Nov;24(22 Suppl):S483-S488.
RECENT RESEARCH
2009 Founder: NOVA SOUTHEASTERN UNIVERSITY RESEARCH SLEEP LAB (2007) Respironics
PRINCIPAL INVESTIGATOR OFFICE BASED CLINICAL TRIALS:
Actelion: QUERIX (PULMONARY ARTERIAL HYPERTENSION) REGISTRY: Canadian Heart Research Center
Completed
Actelion: QUORUM: MACITENTAN REGISTRY TRIAL (PULMONARY ARTERIAL HYPERTENSION): Canadian Heart Research Centre, Completed
Actelion: OPUS: Macitentan (PULMONARY ARTERIAL HYPERTENSION) Completed
Actelion: SPHERE: Uptravi Registry Trial (PULMONARY ARTERIAL HYPERTENSION) Completed
2019 GSK: Asthma Control in Pulmonary and Allergy Clinics in the United States study (Protocol HO-18-18558)
2021 Insmed: ASPEN Study: Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis (Recruiting)
PRINCIPAL INVESTIGATOR COVID-19 HOSPITAL BASED CLINICAL TRIALS:
2020 AstraZeneca: CALAVI, (Acalabrutinib COVID-19) Completed with Holy Cross
2020 GSK: OSCAR,(Otilimab for severe COVID-19 Pneumonia) with Broward Health Medical Center
2020 Genentech/Roche WA42511 - Remdesivir plus Tocilizumab with Severe Covid-19 Pneumonia
SUBPRINCIPAL INVESTIGATOR
2020 Gilead Sciences, Inc. GS-US-553-9020 - Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
PRINCIPAL INVESTIGATOR OFFICE/HOSPITAL BASED CLINICAL TRIALS:
Office Based: Active:
2022 - AZ: OBERON A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of xxx in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations.
2022 - GSK MATINEE A multi-center, randomized, double-blind, parallel-group, placebo-controlled study of mepolizumab 100 mg SC -as add-on treatment in participants with COPD experiencing frequent exacerbations and characterized by eosinophil levels. Enrollment Closed
2022 - SANOFI AERIFY 1 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 /REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1) Enrollment Closed
2023 - GSK NIMBLE GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE) Enrollment Closed
2024 -GSK CALM-2 CHRONIC COUGH STUDYPhase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
2024 - AZ: PROSPERO A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) and STUDY DRUG: Tozorakimab (Extension Trial Oberon)
2024 - AZ:THARROS A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
2024 - SANOFI ACT18018 A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis (Phase 2)
2025 - SANOFI AIRLYMPUS ACT18018 Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
COMPLETED CLOSED STUDIES as PRINCIPAL INVESTIGATOR:
OFFICE BASED
Actelion: QUERIX (PULMONARY ARTERIAL HYPERTENSION) REGISTRY: Canadian Heart Research Center
Actelion: QUORUM: MACITENTAN REGISTRY TRIAL (PULMONARY ARTERIAL HYPERTENSION): Canadian Heart Research Center
Actelion: OPUS: Macitentan (PULMONARY ARTERIAL HYPERTENSION)
Actelion: SPHERE: Uptravi Registry Trial (PULMONARY ARTERIAL HYPERTENSION)
2019 GSK: Asthma Control in Pulmonary and Allergy Clinics in the United States study (Protocol HO-18-18558)
2022 - INSMED:ASPEN- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis.
2022 - AZ: BURAN Effects of xxx on AiRwAy DyNamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters
2022 - SANOFI AERIFY 1 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 /REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1) Enrollment Closed
COMPLETED CLOSED HOSPITAL BASED COVID STUDIES
as PRINCIPAL INVESTIGATOR:
2020 AstraZeneca: CALAVI, (Acalabrutinib COVID-19) Completed with Holy Cross
2020 GSK: OSCAR, (Otilimab for severe COVID-19 Pneumonia) with Broward Health Medical Center
as SUB-PRINCIPAL INVESTIGATOR:
2020 Genentech/Roche WA42511 - Remdesivir plus Tocilizumab with Severe Covid-19 Pneumonia Holy Cross
2020 Gilead Sciences, Inc. GS-US-553-9020 - Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation. Holy Cross
UNIVERSITY AFFILIATIONS
Nova Southeastern University
2004 - Assistant Professor of Medicine
2009 - Associate Professor of Medicine
2011 - Full Clinical Professor of Medicine
Albert Einstein College of Medicine
2002 - Assistant Professor of Medicine
Awards
2009 President’s Award from Nova Southeastern University for our work and this enabled us to open the sleep lab with this and to receive a grant from Respironics.
Caducean Society of greater fort lauderdale
President 2015-2016
(2016) MARK E. UNIS AWARD The award is given in recognition to the physician who upholds the ideals of the Society through the succinct, effective sharing of medical knowledge